不是的，$Pulmatrix, Inc.(PULM)$ 的10-K filing说Mylan撤了，利空。Form strategic alliances to advance clinical trials for our therapeutic candidates for COPD. We had a strategic collaboration with Mylan N.V. (“Mylan”) to advance the clinical development of PUR0200, our lead COPD bronchodilator candidate, in Europe for pharmacokinetics equivalence regulatory pathway. Under the strategic collaboration, we completed a pilot bioequivalence study of PUR0200 with Mylan in Europe in May 2016. As part of the collaboration, Mylan had an option to negotiate the exclusive right to develop, manufacture, commercialize and market any resulting products of PUR0200 outside the United States. Mylan’s option has expired and Pulmatrix owns the exclusive right to develop, manufacture, commercialize and market any resulting products of PUR0200. We intend to form strategic collaborations with third parties with respect to the clinical development of PUR0200 in the United States and outside the United States. （我最近是多么爱读filing啊.....）